Home >

Welcome to ASCO Connection Discussion

LOGIN TO START A DISCUSSION
Filter by Molecular Oncology Tumor Board
Molecular Oncology Tumor Board
ASCO University
Aug 12, 2015 9:39 AM
Read more to answer the following questions: 1) What tumor types should be considered in the differential diagnosis of a CK7+ CK20- CUP? 2)Could you have performed additional immunohistochemical stains to try to determine the site of origin? 3) Is EML4-ALK fusion unique to lung adenocarcinomas? 4) ...
Molecular Oncology Tumor Board
ASCO University
Jul 15, 2015 10:53 AM
Read more to answer the following questions: 1.) What is the role of Arv7 in the resistance to hormonal therapy? 2.) What are the potential treatment implications of patient who possess the ARV7 splice variant? 3.) What is the role of ArV7 in the response to cytotoxic agents such as docetaxel?

 
Molecular Oncology Tumor Board
ASCO University
Jun 10, 2015 9:50 AM
Read more to answer the following: 1) What are the most important prognostic features for this type of ovarian cancer at diagnosis? 2)How would you classify this patient: sensitive or resistant to platinum-based chemotherapy?  Provide your definition of platinum resistance. 3)What would be your...
Molecular Oncology Tumor Board
ASCO University
May 13, 2015 8:54 AM
Read more to answer the following: 1)Was there a role for adjuvant therapy after his original surgery? If yes, what adjuvant chemotherapy would you recommend and why? 2)What treatment would you recommend now? 3)What additional information or testing would you want?
Molecular Oncology Tumor Board
ASCO University
Apr 15, 2015 9:56 AM
Read more to answer the following:
1) Did this patient meet the standard criteria for initiation of therapy for his CLL? 2) What genetic tests were indicated prior to initial treatment of the patient’s CLL? 3) Do you consider fludarabine monotherapy to be a suitable therapy for this patient in 2015?

Pages

Tweets from ASCO

Tweets from Oncology Community